This study investigates the neutralizing activity against the XBB1. 5 variant and the ancestral
strain in a population post-bivalent vaccination using a pseudo virus assay validated with …

COVID-19 vaccines have recently been updated with the spike protein of SARS-CoV-2 XBB.
1.5 subvariant alone, but their immunogenicity in humans has yet to be fully evaluated and …

COVID-19 inactivated vaccines have been extensively administered in China. However, the
majority of the Chinese population has experienced breakthrough infections from SARS …

SARS-CoV-2-neutralizing antibodies were substantially expanded one month after a shot of
XBB. 1.5 monovalent mRNA vaccine (XBB. 1.5 MV) booster, but the durability of this …

Although WHO declared the end of the public health emergency for coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

COVID-19 vaccines have recently been updated to specifically encode or contain the spike
protein of the SARS-CoV-2 XBB. 1.5 subvariant, but their immunogenicity in humans has yet …

As the SARS-CoV-2 virus continues to evolve, novel XBB sub-lineages such as XBB. 1.5,
XBB. 1.16, EG. 5, HK. 3 (FLip), and XBB. 2.3, as well as the most recent BA. 2.86, have been …

The swift emergence of XBB. 1.5 highlights the rapid mutation dynamics of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Renewed urgency led to development …

As coronavirus disease-2019 (COVID-19) becomes an endemic disease, the virus continues
to evolve and become immunologically distinct from previous strains. Immune imprinting has …

As severe acute respiratory coronavirus 2 (SARS-CoV-2) variants continue to emerge, it is
important to characterize immune responses against variants which can inform on protection …